Cargando…
Recurrent SERPINB3 and SERPINB4 Mutations in Patients that Respond to Anti-CTLA4 Immunotherapy
Immune checkpoint blockade has shown significant promise as an anti-cancer treatment, yet the determinants of response are not completely understood. Here, we show that somatic mutations in SERPINB3 and SERPINB4 are associated with survival following anti-CTLA4 immunotherapy in two independent cohor...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553281/ https://www.ncbi.nlm.nih.gov/pubmed/27668655 http://dx.doi.org/10.1038/ng.3677 |
_version_ | 1783256604173402112 |
---|---|
author | Riaz, Nadeem Havel, Jonathan J. Kendall, Sviatoslav M. Makarov, Vladimir Walsh, Logan A. Desrichard, Alexis Weinhold, Nils Chan, Timothy A. |
author_facet | Riaz, Nadeem Havel, Jonathan J. Kendall, Sviatoslav M. Makarov, Vladimir Walsh, Logan A. Desrichard, Alexis Weinhold, Nils Chan, Timothy A. |
author_sort | Riaz, Nadeem |
collection | PubMed |
description | Immune checkpoint blockade has shown significant promise as an anti-cancer treatment, yet the determinants of response are not completely understood. Here, we show that somatic mutations in SERPINB3 and SERPINB4 are associated with survival following anti-CTLA4 immunotherapy in two independent cohorts of melanoma patients (n=174). Interestingly, serpins are homologues of the well-known ovalbumin antigen and are associated with autoimmunity. Our findings have implications for the personalization of immunotherapy. |
format | Online Article Text |
id | pubmed-5553281 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
record_format | MEDLINE/PubMed |
spelling | pubmed-55532812017-08-11 Recurrent SERPINB3 and SERPINB4 Mutations in Patients that Respond to Anti-CTLA4 Immunotherapy Riaz, Nadeem Havel, Jonathan J. Kendall, Sviatoslav M. Makarov, Vladimir Walsh, Logan A. Desrichard, Alexis Weinhold, Nils Chan, Timothy A. Nat Genet Article Immune checkpoint blockade has shown significant promise as an anti-cancer treatment, yet the determinants of response are not completely understood. Here, we show that somatic mutations in SERPINB3 and SERPINB4 are associated with survival following anti-CTLA4 immunotherapy in two independent cohorts of melanoma patients (n=174). Interestingly, serpins are homologues of the well-known ovalbumin antigen and are associated with autoimmunity. Our findings have implications for the personalization of immunotherapy. 2016-09-26 2016-11 /pmc/articles/PMC5553281/ /pubmed/27668655 http://dx.doi.org/10.1038/ng.3677 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Riaz, Nadeem Havel, Jonathan J. Kendall, Sviatoslav M. Makarov, Vladimir Walsh, Logan A. Desrichard, Alexis Weinhold, Nils Chan, Timothy A. Recurrent SERPINB3 and SERPINB4 Mutations in Patients that Respond to Anti-CTLA4 Immunotherapy |
title | Recurrent SERPINB3 and SERPINB4 Mutations in Patients that Respond to Anti-CTLA4 Immunotherapy |
title_full | Recurrent SERPINB3 and SERPINB4 Mutations in Patients that Respond to Anti-CTLA4 Immunotherapy |
title_fullStr | Recurrent SERPINB3 and SERPINB4 Mutations in Patients that Respond to Anti-CTLA4 Immunotherapy |
title_full_unstemmed | Recurrent SERPINB3 and SERPINB4 Mutations in Patients that Respond to Anti-CTLA4 Immunotherapy |
title_short | Recurrent SERPINB3 and SERPINB4 Mutations in Patients that Respond to Anti-CTLA4 Immunotherapy |
title_sort | recurrent serpinb3 and serpinb4 mutations in patients that respond to anti-ctla4 immunotherapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553281/ https://www.ncbi.nlm.nih.gov/pubmed/27668655 http://dx.doi.org/10.1038/ng.3677 |
work_keys_str_mv | AT riaznadeem recurrentserpinb3andserpinb4mutationsinpatientsthatrespondtoantictla4immunotherapy AT haveljonathanj recurrentserpinb3andserpinb4mutationsinpatientsthatrespondtoantictla4immunotherapy AT kendallsviatoslavm recurrentserpinb3andserpinb4mutationsinpatientsthatrespondtoantictla4immunotherapy AT makarovvladimir recurrentserpinb3andserpinb4mutationsinpatientsthatrespondtoantictla4immunotherapy AT walshlogana recurrentserpinb3andserpinb4mutationsinpatientsthatrespondtoantictla4immunotherapy AT desrichardalexis recurrentserpinb3andserpinb4mutationsinpatientsthatrespondtoantictla4immunotherapy AT weinholdnils recurrentserpinb3andserpinb4mutationsinpatientsthatrespondtoantictla4immunotherapy AT chantimothya recurrentserpinb3andserpinb4mutationsinpatientsthatrespondtoantictla4immunotherapy |